---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-006482"
form_type: "8-K"
ticker: "VYGR"
cik: "0001640266"
company_name: "Voyager Therapeutics, Inc."
filed_at: "2025-05-06T23:59:59+00:00"
generated_at: "2026-05-22T12:23:47.106383+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Voyager Q1 2025 net loss $31.0M, revenue down 67% YoY; cash $295M into mid-2027

## Summary
- Net loss $31.0M vs $11.3M YoY; collaboration revenue $6.5M vs $19.5M YoY (−67%).
- Cash, cash equivalents & marketable securities $295M; expects runway into mid-2027.
- R&D expenses $31.5M (+16% YoY); G&A $9.6M (+12% YoY).
- VY1706 tau silencing gene therapy achieved up to 73% tau mRNA knockdown in NHPs; IND/CTA filings expected 2026.
- Neurocrine-partnered FA and GBA1 IND submissions on track for 2025; up to $35M milestone potential 2025-2026.

## SEC filing metadata
- accession: 0001558370-25-006482
- form_type: 8-K
- ticker: VYGR
- cik: 0001640266
- company_name: Voyager Therapeutics, Inc.
- filed_at: 2025-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1640266/000155837025006482/0001558370-25-006482-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1640266/000155837025006482/vygr-20250506x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-006482
- JSON: https://secwatch.observer/filing/0001558370-25-006482.json
- Plain text: https://secwatch.observer/filing/0001558370-25-006482.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.